Topoisomerase II Inhibitors
"Topoisomerase II Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
| Descriptor ID |
D059005
|
| MeSH Number(s) |
D27.505.519.389.892.750 D27.505.954.248.794.750
|
| Concept/Terms |
Topoisomerase II Inhibitors- Topoisomerase II Inhibitors
- Inhibitors, Topoisomerase II
- DNA Type 2 Topoisomerase Inhibitors
- Topoisomerase 2 Inhibitors
- Inhibitors, Topoisomerase 2
- DNA Topoisomerase II Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase II Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase II Inhibitors".
This graph shows the total number of publications written about "Topoisomerase II Inhibitors" by people in this website by year, and whether "Topoisomerase II Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 3 | 4 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 4 | 1 | 5 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase II Inhibitors" by people in Profiles.
-
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria. J Med Chem. 2020 07 23; 63(14):7773-7816.
-
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500.
-
Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother. 2019 Sep; 20(13):1637-1644.
-
TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519.
-
The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan; 83(1):225-34.
-
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012 Jun; 97(6):919-25.
-
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol. 2008 Jun; 31(3):219-25.
-
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80.
-
Assessing sensitivity to antibacterial topoisomerase II inhibitors. Curr Protoc Pharmacol. 2007 Dec; Chapter 3:Unit3.13.
-
Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007 Jul; 114(7):1378-83.